Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pheochromocytoma × lanreotide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 8 Carcinoid Tumor 3 Acromegaly 3 Pituitary Neoplasms 2 Carcinoma, Hepatocellular 2 Pheochromocytoma 1 Paraganglioma 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Neoplasm Metastasis 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Carcinoma, Merkel Cell 1

Interventions

3-Iodobenzylguanidine 7 lutetium Lu 177 dotatate 3 Temozolomide 3 Phenoxybenzamine 3 pegfilgrastim 2 anlotinib 2 Granulocyte Colony-Stimulating Factor 2 Everolimus 2 Doxazosin 2 Dexmedetomidine 2 Capecitabine 2 Adrenalectomy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 veliparib 1 vatalanib 1 temsirolimus 1 pentetreotide 1 penpulimab 1 olaparib 1 lenvatinib 1 lanreotide 1 gallium Ga 68 dotatate 1 fluorodopa F 18 1 fludarabine phosphate 1 cabozantinib 1 belzutifan 1 atezolizumab 1 Vorinostat 1 Vinorelbine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03946527 2026-03-02

LAMPARA

Columbia University

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡